KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer ; volume:42 ; number:3 ; day:26 ; month:3 ; year:2024 ; pages:261-271 ; date:6.2024
Investigational new drugs ; 42, Heft 3 (26.3.2024), 261-271, 6.2024
- Creator
-
Yamamoto, Noboru
Satouchi, Miyako
Doi, Toshihiko
Fujiwara, Yutaka
Yanagitani, Noriko
Kawa, Yoshitaka
Yoh, Kiyotaka
Leopold, Lance
Munteanu, Mihaela
Sawada, Takashi
Han, Shirong
Noguchi, Kazuo
Nishio, Makoto
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-024-01422-6
- URN
-
urn:nbn:de:101:1-2408162212228.450770791321
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
29.08.2023252, 9:10 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yamamoto, Noboru
- Satouchi, Miyako
- Doi, Toshihiko
- Fujiwara, Yutaka
- Yanagitani, Noriko
- Kawa, Yoshitaka
- Yoh, Kiyotaka
- Leopold, Lance
- Munteanu, Mihaela
- Sawada, Takashi
- Han, Shirong
- Noguchi, Kazuo
- Nishio, Makoto
- SpringerLink (Online service)
Other Objects (12)
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Role of Crizotinib in previously treated non-small-cell lung cancer
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Role of Crizotinib in previously treated non-small-cell lung cancer
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Role of Crizotinib in previously treated non-small-cell lung cancer
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion